A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma - PubMed (original) (raw)
Clinical Trial
. 2006 Dec 1;12(23):7046-53.
doi: 10.1158/1078-0432.CCR-06-1571.
Christos Emmanouilides, Don M Benson Jr, Deborah Hurst, Pablo Garcia, Glenn Michelson, Sandra Milan, Amy K Ferketich, Lawrence Piro, John P Leonard, Pierluigi Porcu, Charles F Eisenbeis, Amy L Banks, Lei Chen, John C Byrd, Michael A Caligiuri
Affiliations
- PMID: 17145827
- DOI: 10.1158/1078-0432.CCR-06-1571
Clinical Trial
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma
Khuda D Khan et al. Clin Cancer Res. 2006.
Abstract
Purpose: The incidence of non-Hodgkin's lymphoma (NHL), the fifth most common malignancy in the United States, has increased over 70% in the last 30 years. Fifty percent to 75% of patients with low-grade or follicular NHL respond to rituximab therapy. However, responses are generally of limited duration, and complete responses are rare. Preclinical work suggests that human recombinant interleukin-2 (rIL-2; aldesleukin, Proleukin) enhances rituximab efficacy. Antibody-dependent cellular cytotoxicity (ADCC) is an important mechanism of action of rituximab. rIL-2 induces expansion and activation of Fc receptor (FcR)-bearing cells, thereby enhancing ADCC. Therefore, a large, multicenter phase 2 trial to assess the effects of rIL-2 on rituximab therapy in patients with rituxumab-refractory low-grade NHL was conducted.
Experimental design: The combination of rituximab and rIL-2 was studied in 57 patients with rituximab-refractory low-grade NHL (i.e., patients must have received a single-agent course of rituximab and showed no tumor response, or had a response lasting <6 months). I.V. rituximab was given at 375 mg/m(2) (weeks 1-4). S.C. rIL-2 was given thrice a week at 14 MIU (weeks 2-5) and at 10 MIU (weeks 6-9).
Results: Rituximab plus rIL-2 combination therapy was safe and generally well tolerated, but responses were low. Fifty-seven patients were enrolled with 54 evaluable for response; however, only five responses (one complete and four partial) were observed. Correlative data indicate that rIL-2 expanded FcR-bearing cells and enhanced ADCC. However, other factors, such as FcgammaR polymorphisms in patients refractory to single-agent rituxumab and heterogeneous tumor biology, may have influenced the lack of clinical efficacy seen with this combination therapy.
Conclusions: rIL-2 expands FcR-bearing cellular subsets in vivo and enhances in vitro ADCC of rituxumab. However, these findings do not directly translate into meaningful clinical benefit for patients with rituxumab-refractory NHL.
Similar articles
- Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL. Lopes de Menezes DE, et al. J Immunother. 2007 Jan;30(1):64-74. doi: 10.1097/01.cji.0000211315.21116.07. J Immunother. 2007. PMID: 17198084 - Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P. Eisenbeis CF, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6101-10. doi: 10.1158/1078-0432.CCR-04-0525. Clin Cancer Res. 2004. PMID: 15447996 Clinical Trial. - Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS. Rummel MJ, et al. J Clin Oncol. 2005 May 20;23(15):3383-9. doi: 10.1200/JCO.2005.08.100. J Clin Oncol. 2005. PMID: 15908650 Clinical Trial. - The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R, Hagenbeek A. Marcus R, et al. Eur J Haematol Suppl. 2007 Jan;(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x. Eur J Haematol Suppl. 2007. PMID: 17206982 Review. - Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K. Tobinai K. Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S90-6. doi: 10.1007/s00280-003-0595-y. Epub 2003 Jun 18. Cancer Chemother Pharmacol. 2003. PMID: 12819934 Review.
Cited by
- Identification of Novel Risk Variants of Inflammatory Factors Related to Myeloproliferative Neoplasm: A Bidirectional Mendelian Randomization Study.
Li Y, Sun T, Chen J, Zhang L. Li Y, et al. Glob Med Genet. 2024 Feb 12;11(1):48-58. doi: 10.1055/s-0044-1779665. eCollection 2024 Jan. Glob Med Genet. 2024. PMID: 38348158 Free PMC article. - A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes.
Laoharawee K, Johnson MJ, Lahr WS, Sipe CJ, Kleinboehl E, Peterson JJ, Lonetree CL, Bell JB, Slipek NJ, Crane AT, Webber BR, Moriarity BS. Laoharawee K, et al. Int J Mol Sci. 2022 Aug 28;23(17):9749. doi: 10.3390/ijms23179749. Int J Mol Sci. 2022. PMID: 36077152 Free PMC article. - Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives.
Atallah-Yunes SA, Robertson MJ. Atallah-Yunes SA, et al. Front Immunol. 2022 Apr 20;13:872010. doi: 10.3389/fimmu.2022.872010. eCollection 2022. Front Immunol. 2022. PMID: 35529882 Free PMC article. Review. - Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity.
Wang Z, Yin C, Lum LG, Simons A, Weiner GJ. Wang Z, et al. J Hematol Oncol. 2021 Dec 9;14(1):204. doi: 10.1186/s13045-021-01216-w. J Hematol Oncol. 2021. PMID: 34886888 Free PMC article. - T cells, particularly activated CD4+ cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity.
Wang Z, Chimenti MS, Strouse C, Weiner GJ. Wang Z, et al. Cancer Immunol Immunother. 2022 Feb;71(2):237-249. doi: 10.1007/s00262-021-02976-7. Epub 2021 Jun 10. Cancer Immunol Immunother. 2022. PMID: 34110453 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources